Cellectis (NASDAQ:CLLS) Releases Earnings Results, Misses Estimates By $0.22 EPS

Cellectis (NASDAQ:CLLS - Get Free Report) announced its earnings results on Thursday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.06 by ($0.22), Zacks reports. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The business had revenue of $33.22 million for the quarter, compared to analysts' expectations of $5.90 million.

Cellectis Price Performance

NASDAQ CLLS traded up $0.05 during mid-day trading on Tuesday, hitting $1.27. The stock had a trading volume of 240,147 shares, compared to its average volume of 136,677. The firm's 50 day moving average is $1.49 and its 200 day moving average is $1.79. Cellectis has a twelve month low of $1.14 and a twelve month high of $3.38. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78. The stock has a market capitalization of $70.59 million, a price-to-earnings ratio of -0.98 and a beta of 3.27.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on Cellectis in a research note on Thursday, February 27th. They issued a "buy" rating for the company.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.